USNA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
USNA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Usana Health Sciences's change in receivables for the quarter that ended in Dec. 2023 was $0.0 Mil. It means Usana Health Sciences's Accounts Receivable stayed the same from Sep. 2023 to Dec. 2023 .
Usana Health Sciences's change in receivables for the fiscal year that ended in Dec. 2023 was $0.0 Mil. It means Usana Health Sciences's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .
Usana Health Sciences's Accounts Receivable for the quarter that ended in Dec. 2023 was $0.0 Mil.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Usana Health Sciences's Days Sales Outstanding for the three months ended in Dec. 2023 was 0.00.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Usana Health Sciences's liquidation value for the three months ended in Dec. 2023 was $225.6 Mil.
The historical data trend for Usana Health Sciences's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Usana Health Sciences (NYSE:USNA) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Usana Health Sciences's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 0 | / | 221.083 | * | 91 |
= | 0.00 |
2. In Ben Graham's calculation of liquidation value, Usana Health Sciences's accounts receivable are only considered to be worth 75% of book value:
Usana Health Sciences's liquidation value for the quarter that ended in Dec. 2023 is calculated as:
Liquidation Value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 330.42 | - | 135.555 | + | 0.75 * 0 | + | 0.5 * 61.454 |
= | 225.6 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Usana Health Sciences's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.
John Turman Fleming | director | 3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120 |
Gilbert A Fuller | officer: CFO and Executive V.P. | 55 WANDERWOOD WAY, SANDY UT 84092 |
Frederic J Winssinger | director | 2944 N 44TH STREET, SUITE 250, PHOENIX AZ 85018 |
David Mulham Mulham | officer: Chief Field Development Office | 3838 WEST PARKWAY BLVD, SALT LAKE CITY UT 84120 |
Paul A. Jones | officer: CFO | 3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120 |
Xia Ding | director | 3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120 |
Daniel A. Macuga | officer: Chief Communications Officer | 3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120 |
Jim Brown | officer: Chief Production Officer | 3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120 |
Brent Neidig | officer: CO & Man. Dir. of China | 3838 WEST PARKWAY BLVD., WEST VALLEY CITY UT 84120 |
J Scott Nixon | director | 757 EAST SOUTH TEMPLE, SUITE 150, SALT LAKE CITY UT 84102 |
Kevin Guest | officer: E.V.P. of Marketing | 3838 WEST PARKWAY BLVD, SALT LAKE CITY UT 84120 |
Joshua Foukas | officer: Chief Legal Officer | 3838 WEST PARKWAY BLVD., SALT LAKE CITY X1 84120 |
G Doug Iiekking | officer: VP of Finance | C/O USANA HEALTH SCIENCES INC, 3838 W PARKWAY BLVD, SALT LAKE CITY UT 84120 |
Walter Noot | officer: Chief Information Officer | 3838 WEST PARKWAY BLVD, SALT LAKE CITY UT 84120 |
Robert A Sinnott | officer: Chief Scientific Officer | 400 55 WATER STREET, VANCOUVER A1 V6B1A1 |
From GuruFocus
By PRNewswire 05-24-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.